{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:12:37Z","timestamp":1789013557741,"version":"build-2803163510"},"reference-count":21,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2023,5,12]]},"DOI":"10.1080\/10428194.2023.2197090","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T12:16:00Z","timestamp":1681388160000},"page":"1123-1128","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data"],"prefix":"10.1080","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7128-1255","authenticated-orcid":false,"given":"Fieke W.","family":"Hoff","sequence":"first","affiliation":[{"name":"Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA"},{"name":"Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prapti A.","family":"Patel","sequence":"additional","affiliation":[{"name":"Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA"},{"name":"Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Belli","sequence":"additional","affiliation":[{"name":"COTA, Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hansen","sequence":"additional","affiliation":[{"name":"COTA, Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Foss","sequence":"additional","affiliation":[{"name":"COTA, Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Schulte","sequence":"additional","affiliation":[{"name":"COTA, Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Kun","family":"Wang","sequence":"additional","affiliation":[{"name":"COTA, Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan F.","family":"Madanat","sequence":"additional","affiliation":[{"name":"Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA"},{"name":"Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.04.005"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01474-9"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00555-8"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26039"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016963"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-379008"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-3-10"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000243"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26190"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007265"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac135"},{"key":"CIT0014","volume-title":"FDA approves venetoclax in combination for AML in adults","year":"2018"},{"key":"CIT0015","doi-asserted-by":"crossref","unstructured":"Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et\u00a0al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16):3187\u20133205.","DOI":"10.1182\/blood-2012-03-362608"},{"key":"CIT0016","doi-asserted-by":"crossref","unstructured":"Bataller A, Garrido A, Guijarro F, et\u00a0al. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Adv. 2022;6(4):1193\u20131206.","DOI":"10.1182\/bloodadvances.2021005585"},{"key":"CIT0017","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Estey E, Grimwade D, et\u00a0al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood Adv. 2017;129(4):424\u2013447.","DOI":"10.1182\/blood-2016-08-733196"},{"key":"CIT0018","doi-asserted-by":"crossref","unstructured":"Wei AH, Montesinos P, Ivanov V, et\u00a0al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137\u20132145.","DOI":"10.1182\/blood.2020004856"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01600"},{"key":"CIT0020","unstructured":"Fieke W. Hoff, Prapti A. Patel, Eric Hansen, et al. Agreement between real-world physician response assessment and the 2022 European LeukemiaNet (ELN) criteria in acute myeloid leukemia, 2022."},{"key":"CIT0021","doi-asserted-by":"crossref","unstructured":"DiNardo C., Tiong I., Quaglieri A, et\u00a0al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135(11):791\u2013803.","DOI":"10.1182\/blood.2019003988"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2023.2197090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T01:53:25Z","timestamp":1686534805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2023.2197090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,5,12]]}},"alternative-id":["10.1080\/10428194.2023.2197090"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2023.2197090","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-01-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}